Osztie E, Várallyay P, Doolittle N D, Lacy C, Jones G, Nickolson H S, Neuwelt E A
Department of Neurology, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 92701, USA.
AJNR Am J Neuroradiol. 2001 May;22(5):818-23.
Optic pathway and/or hypothalamic astrocytomas in children are often quiescent, but in some cases, more aggressive tumors may cause progressive visual, endocrine, and neurologic deterioration. The initial treatment of these gliomas includes surgery and IV chemotherapy. Radiotherapy is not recommended in young children because of its severe adverse effects on cognitive and neuroendocrine function. This report suggests a new approach using combined intraarterial and IV carboplatin-based chemotherapy for patients for whom first line treatment has already failed.
Six children (mean age, 57 months) with the diagnosis of optic pathway hypothalamic gliomas, who had tumor progression after surgery and underwent IV chemotherapy, were treated monthly with intraarterially administered carboplatin, intraarterially administered etoposide phosphate, and IV administered Cytoxan. Four of the children had histologically verified pilocytic astrocytomas, and in two cases, diagnosis was made on the basis of clinical findings. Administration of the intraarterial chemotherapy required catheter placement in both internal carotid arteries at the level of C2-C3 and into one of the vertebral arteries at the level of C6-C7, with the patient under general anesthesia.
Four of six patients had partial radiographic response, one had stable disease, and one had progressive disease after one cycle. Three patients showed clinical improvement. There were no serious complications associated with the angiographic procedures. Toxicities included bronchospasm that resolved after 3 to 4 minutes in one patient. One patient showed mild ototoxicity, and four patients needed platelet transfusion because of hematologic toxicity of drugs.
These results suggest that this modality of chemotherapy (administered after failure of systemic [ie, IV] chemotherapy), of progressive optic-hypothalamic astrocytomas in young children may be an effective treatment prior to radiotherapy.
儿童视路和/或下丘脑星形细胞瘤通常生长缓慢,但在某些情况下,侵袭性较强的肿瘤可能导致进行性视力、内分泌及神经功能恶化。这些胶质瘤的初始治疗包括手术和静脉化疗。由于放疗对认知和神经内分泌功能有严重不良反应,不建议对幼儿使用。本报告提出一种新方法,即对一线治疗失败的患者联合使用动脉内和静脉内基于卡铂的化疗。
6名诊断为视路下丘脑胶质瘤的儿童(平均年龄57个月),术后肿瘤进展且接受过静脉化疗,每月接受动脉内给予卡铂、动脉内给予磷酸依托泊苷以及静脉给予环磷酰胺治疗。其中4名儿童经组织学证实为毛细胞型星形细胞瘤,2例根据临床表现确诊。动脉化疗给药时,患者需在全身麻醉下,将导管置于双侧颈内动脉C2 - C3水平以及一侧椎动脉C6 - C7水平。
6名患者中,4名影像学部分缓解,1名病情稳定,1名在1个周期后病情进展。3名患者临床症状改善。血管造影操作未出现严重并发症。毒性反应包括1名患者出现3至4分钟后缓解的支气管痉挛。1名患者有轻度耳毒性,4名患者因药物血液学毒性需要输注血小板。
这些结果表明,这种化疗方式(在全身[即静脉]化疗失败后使用)对幼儿进展性视路下丘脑星形细胞瘤可能是放疗前的一种有效治疗方法。